Overview

• REDEFINE 1 data presented at the American Diabetes Association meeting showed CagriSema achieved a 20.4% average body weight reduction over 68 weeks, with nearly two-thirds of participants losing more than 20%.
• Gastrointestinal side effects were mainly mild to moderate, resulting in a 6% to 8% discontinuation rate that mirrors profiles seen with existing GLP-1 therapies.
• Novo Nordisk plans to seek regulatory approval for CagriSema early next year and has initiated the REDEFINE 11 trial to assess extended treatment duration and additional weight-loss potential.
• Early trials of amycretin—an experimental dual GLP-1/amylin agonist—reported an average 13.1% weight loss at 36 weeks for weekly injections and 5.3% over 12 weeks with a high-dose oral regimen.
• Shares fell as much as 7.1% in premarket trading after detailed results raised investor concerns about tolerability and a projected 2027 launch lagging behind Eli Lilly’s Zepbound.